It is a shame and a crime that L1 is not readily available to patients in the US and Canada. The reasons why have been stated in my prior post at
http://www.thalassemiapatientsandfriends.com/index.php?topic=1317.msg10624#msg10624Dr Olivieri has been portrayed as a martyr and a hero and in my opinion she is neither when it comes to this topic. She is a fine thalassemia doctor but her blind stubbornness may have cost patients their lives. Every study ever done about L1, other than her own questionable study, has shown that it works and is safe when patients are properly monitored. Olivieri's refusal to admit she was wrong has helped deprive thals of a much needed chelator.
L1 should be approved. There is no other iron chelator that removes iron from the heart as well as L1. Heart failure is the number one killer of thals. This is a no-brainer. Withholding this medicine is downright criminal!
I would also like to clear up some misconceptions about the Exjade report. This is a new report that was only just released on March 7, 2008. The 24 cases of liver failure due to Exjade use have not previously been reported. The report and new recommendations that were released in January of 2007 concerned kidney failure in Exjade users, not liver failure, The only prior reports of liver failure concerned patients over the age of 55. This new information has only been released in Canada and only after prompting by the Canadian authorities. This information is crucial to patients who have liver disease (hepatitis for example). Whereas this information won't mean any changes for patients with healthy livers, it does mean much for older patients who need to be informed, along with their doctors that Exjade can lead to liver failure when the liver is already sick or damaged. Any changes in liver levels must be noted and with any significant change, Exjade must be interrupted.
This new information is significant for older patients who may have liver problems. There has been nothing in this information or the prior information about kidney failure, that should worry patients who are in good health. No patient without liver problems has had any recorded incidents of liver failure from Exjade.
Novartis does recognize that the 24 cases are probably not all that have occurred and they do request that doctors and patients report ALL adverse reactions (not things like the rash, unless severe).
http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2008/exjade_2_hpc-cps-eng.phpManaging marketed health product-related adverse reactions depends on health care professionals and consumers reporting them, in addition to reports collected from clinical trials. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health products. If you have had a serious or unexpected reaction to EXJADE* you may notify either Novartis Pharmaceuticals Canada Inc. or Health Canada as follows:
Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd.
Dorval, (QC) H9S 1A9
Phone: 1-800-363-8883
Any suspected adverse incident can also be reported to:
Canada Vigilance Program
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
Ottawa, Ontario, K1A 0K9
Tel: 613-957-0337 or Fax: 613-957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
CanadaVigilance@hc-sc.gc.ca
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
For other inquiries related to this communication, please contact Health Canada at:
Bureau of Metabolism, Oncology and Reproductive Sciences
Therapeutic Products Directorate
E-mail: BMORS_Enquiries@hc-sc.gc.ca
Tel: 613-941-3171
Fax: 613-941-1365
For media inquiries, please contact Silvie Letendre at (514) 633-7872.